{"id":"NCT01263015","sponsor":"ViiV Healthcare","briefTitle":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","officialTitle":"A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02-01","primaryCompletion":"2012-05-14","completion":"2015-12-03","firstPosted":"2010-12-20","resultsPosted":"2014-07-02","lastUpdate":"2018-04-04"},"enrollment":844,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Infection, Human Immunodeficiency Virus I"],"interventions":[{"type":"DRUG","name":"Dolutegravir","otherNames":[]},{"type":"DRUG","name":"Atripla","otherNames":[]},{"type":"DRUG","name":"Abacavir/Lamivudine","otherNames":[]},{"type":"DRUG","name":"Abacavir/Lamivudine Placebo","otherNames":[]},{"type":"DRUG","name":"Dolutegravir placebo","otherNames":[]},{"type":"DRUG","name":"Atripla placebo","otherNames":[]}],"arms":[{"label":"Dolutegravir (N=~394):","type":"EXPERIMENTAL"},{"label":"Atripla (N=~394):","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of Bristol-Myers Squibb and Gilead Sciences LLC) over 48 weeks; non-inferiority will also be tested at Week 96. This study will be conducted in HIV-1 infected ART-naïve adult subjects. Long term antiviral activity, tolerability, safety, and development of viral resistance will be evaluated.","primaryOutcome":{"measure":"Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"DTG 50 mg Plus ABC/3TC 600/300 mg Once Daily","deltaMin":88,"sd":null},{"arm":"EFV/TDF/FTC 600/200/300 mg Once Daily","deltaMin":81,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":145,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Italy","Netherlands","Romania","Spain","United Kingdom"]},"refs":{"pmids":["26262777","24195548"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":65,"n":414},"commonTop":["Dizziness","Diarrhoea","Nasopharyngitis","Nausea","Headache"]}}